In conclusion, both Gankyrin and YAP1 play important roles in tumor metabolism, and Gankyrin-targeted inhibition may be a potential anti-cancer therapeutic strategy for NSCLC. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.